Takeda Pharmaceutical Co Ltd (TAK.US) is planning to book a restructuring charge of approximately 1500 billion yen (around $9.45 billion) in the upcoming new fiscal year starting next month. This move signals a comprehensive business transformation for Japan's largest pharmaceutical company, aimed at boosting efficiency and fostering growth through cost reduction and the adoption of new technologies.
In a statement released on Wednesday, the company indicated that restructuring expenses are expected to decrease after next year. By streamlining corporate functions, Takeda anticipates achieving total annual savings exceeding 2000 billion yen.
The restructuring at Takeda is part of a broader trend among major pharmaceutical firms embracing artificial intelligence, as rising research and development costs squeeze profit margins and intensify market competition. By cutting traditional expenses and reinvesting in new technologies, Takeda aims to free up more capital for R&D.
The company stated that these savings will largely offset the investments required for developing new drugs, such as oveporexton for narcolepsy and zasocitinib for psoriasis. Takeda has reportedly made initial progress in several pipelines, including psoriasis, through collaborations with partners and its internal AI teams. This is viewed by the market as a sign of its transition from a traditional pharmaceutical company to a technology-driven biopharmaceutical enterprise.
Last October, the drugmaker partnered with Boston-based data and AI company TetraScience to accelerate drug discovery and enhance productivity using agent-based AI.
It is noteworthy that Takeda is currently navigating a "patent cliff," particularly after its blockbuster ADHD drug Vyvanse and hypertension treatment Azilva lost exclusivity in key markets. Competition from generic drugs has reduced the company's operating profit by more than half compared to previous years.
To address this challenge, Takeda plans to streamline its global organizational structure, reduce redundant human resources, and simplify management layers. The company aims to gradually increase its core operating profit margin starting from fiscal year 2025, with a long-term goal of stabilizing it above 30%.
Concurrent with the financial restructuring, Takeda has also made forward-looking adjustments to its senior leadership team. The company confirmed that current core executive Julie Kim will assume the role of CEO in June 2026, becoming the first female CEO in the company's history. She will be responsible for leading the implementation of this complex series of reform initiatives.
Analysts suggest that this leadership change complements the restructuring plan, aiming to inject new strategic perspectives into Takeda. This is intended to help the company regain growth momentum through technological empowerment and organizational optimization amid intensifying global pharmaceutical competition.